In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast","authorlink":""},"src":"https:\/\/traffic.libsyn.com\/secure\/helixtalk\/076_-_Tardive_dyskinesia.mp3?dest-id=187168","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202310\/51d8ce-5810-087d-300941_800.png"},"title":"076 - The New Move: Treating Tardive Dyskinesia","link":"javascript:;","id":"item-685429"}]
